FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2978713040> ?p ?o ?g. }

• W2978713040 endingPage "539" @default.
• W2978713040 startingPage "527" @default.
• W2978713040 abstract "Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). In this population, polypharmacy for age-related comorbidities is common and may increase drug-drug interaction (DDI) risks. Preclinical/phase I study data suggest darolutamide has a low DDI potential-other than breast cancer resistance protein/organic anion transporter protein substrates (e.g., statins), no clinically relevant effect on comedications is expected.Our objective was to evaluate the effect of commonly administered drugs on the pharmacokinetics of darolutamide and the effect of comedications potentially affected by darolutamide on safety in patients with nmCRPC.Comorbidities and comedication use in the 1509 ARAMIS participants treated with darolutamide 600 mg twice daily or placebo were assessed. A population pharmacokinetic analysis evaluated whether comedications affected the pharmacokinetics of darolutamide in a subset of 388 patients. A subgroup analysis of adverse events (AEs) in statin users versus nonusers was conducted.Most participants (median age 74 years) had at least one comorbidity (98.4% in both arms) and used at least one comedication (98.7% with darolutamide vs. 98.0% with placebo); these were similar across study arms. Despite frequent use of comedications with DDI potential, no significant effects on darolutamide pharmacokinetics were identified. Comedications included lipid-modifying agents (34.5%), β-blockers (29.7%), antithrombotics (42.8%), and systemic antibiotics (26.9%). AE incidence was similar across study arms in statin users and nonusers. Study limitations include the small sample size for sub-analyses.These analyses suggest the pharmacokinetic profile of darolutamide is not affected by a number of commonly administered drugs in patients with nmCRPC. Although pharmacokinetic data have indicated that darolutamide has the potential to interact with rosuvastatin, used to assess DDI in these studies, this finding did not seem to translate into increased AEs due to statin use in the ARAMIS trial. Clinicaltrials.gov identifier: NCT02200614.Darolutamide is a medicine used to treat men with prostate cancer that has not spread to other parts of the body (nonmetastatic). Often, these patients are taking other medicines for common age-related illnesses. Taking more than one medicine at the same time increases the chances of what is known as drug–drug interactions. Drug–drug interactions can decrease how well the medicines work or may sometimes increase side effects.To test for possible drug–drug interactions in men with prostate cancer who take darolutamide alongside other medicines.Men with nonmetastatic prostate cancer who were being treated with a medicine that lowers testosterone, a chemical in the body that causes prostate cancer tumors to grow. Participants took two darolutamide 300 mg tablets, or an inactive placebo, twice a day.The researchers documented the number of medicines taken by each participant and the number of other medical conditions that they had. Tests were done to find out whether other medicines affected the way that darolutamide works in the body and whether patients taking darolutamide alongside other medicines experienced more side effects.As would be expected, based on the typical age of patients with prostate cancer, more than 90% of participants in this study used medicines other than darolutamide to manage common age-related illnesses or medical conditions. Taking medicines alongside darolutamide did not impact how darolutamide worked in the body and did not increase the number of side effects experienced by patients. Darolutamide is known to interact with rosuvastatin, a cholesterol-lowering drug. However, in this study, there was no overall increase in side effects among darolutamide-treated patients who took this type of drug compared with in those who did not.In this study of patients with nonmetastatic prostate cancer, limited drug–drug interactions were seen when taking darolutamide alongside other medicines given to these patients to manage age-related medical conditions." @default.
• W2978713040 created "2019-10-10" @default.
• W2978713040 creator A5000398172 @default.
• W2978713040 creator A5004503139 @default.
• W2978713040 creator A5006356120 @default.
• W2978713040 creator A5007779528 @default.
• W2978713040 creator A5008439399 @default.
• W2978713040 creator A5011425417 @default.
• W2978713040 creator A5017280045 @default.
• W2978713040 creator A5017925159 @default.
• W2978713040 creator A5019286457 @default.
• W2978713040 creator A5031864797 @default.
• W2978713040 creator A5033341707 @default.
• W2978713040 creator A5040519604 @default.
• W2978713040 creator A5049221780 @default.
• W2978713040 creator A5058719162 @default.
• W2978713040 creator A5064310875 @default.
• W2978713040 creator A5088518998 @default.
• W2978713040 date "2019-09-30" @default.
• W2978713040 modified "2023-10-15" @default.
• W2978713040 title "Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial" @default.
• W2978713040 cites W1970024336 @default.
• W2978713040 cites W1991833417 @default.
• W2978713040 cites W2024015102 @default.
• W2978713040 cites W2127307826 @default.
• W2978713040 cites W2324916026 @default.
• W2978713040 cites W2413476395 @default.
• W2978713040 cites W2551559191 @default.
• W2978713040 cites W2594525893 @default.
• W2978713040 cites W2751952555 @default.
• W2978713040 cites W2792086148 @default.
• W2978713040 cites W2810806599 @default.
• W2978713040 cites W2883863494 @default.
• W2978713040 cites W2891937783 @default.
• W2978713040 cites W2908948837 @default.
• W2978713040 cites W2913767564 @default.
• W2978713040 cites W2947285993 @default.
• W2978713040 cites W2977338802 @default.
• W2978713040 doi "https://doi.org/10.1007/s11523-019-00674-0" @default.
• W2978713040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6797643" @default.
• W2978713040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31571095" @default.
• W2978713040 hasPublicationYear "2019" @default.
• W2978713040 type Work @default.
• W2978713040 sameAs 2978713040 @default.
• W2978713040 citedByCount "50" @default.
• W2978713040 countsByYear W29787130402019 @default.
• W2978713040 countsByYear W29787130402020 @default.
• W2978713040 countsByYear W29787130402021 @default.
• W2978713040 countsByYear W29787130402022 @default.
• W2978713040 countsByYear W29787130402023 @default.
• W2978713040 crossrefType "journal-article" @default.
• W2978713040 hasAuthorship W2978713040A5000398172 @default.
• W2978713040 hasAuthorship W2978713040A5004503139 @default.
• W2978713040 hasAuthorship W2978713040A5006356120 @default.
• W2978713040 hasAuthorship W2978713040A5007779528 @default.
• W2978713040 hasAuthorship W2978713040A5008439399 @default.
• W2978713040 hasAuthorship W2978713040A5011425417 @default.
• W2978713040 hasAuthorship W2978713040A5017280045 @default.
• W2978713040 hasAuthorship W2978713040A5017925159 @default.
• W2978713040 hasAuthorship W2978713040A5019286457 @default.
• W2978713040 hasAuthorship W2978713040A5031864797 @default.
• W2978713040 hasAuthorship W2978713040A5033341707 @default.
• W2978713040 hasAuthorship W2978713040A5040519604 @default.
• W2978713040 hasAuthorship W2978713040A5049221780 @default.
• W2978713040 hasAuthorship W2978713040A5058719162 @default.
• W2978713040 hasAuthorship W2978713040A5064310875 @default.
• W2978713040 hasAuthorship W2978713040A5088518998 @default.
• W2978713040 hasBestOaLocation W29787130401 @default.
• W2978713040 hasConcept C112705442 @default.
• W2978713040 hasConcept C121608353 @default.
• W2978713040 hasConcept C126322002 @default.
• W2978713040 hasConcept C142724271 @default.
• W2978713040 hasConcept C143998085 @default.
• W2978713040 hasConcept C197934379 @default.
• W2978713040 hasConcept C204787440 @default.
• W2978713040 hasConcept C27081682 @default.
• W2978713040 hasConcept C2776551883 @default.
• W2978713040 hasConcept C2778375690 @default.
• W2978713040 hasConcept C2780192828 @default.
• W2978713040 hasConcept C2908647359 @default.
• W2978713040 hasConcept C61367390 @default.
• W2978713040 hasConcept C67761136 @default.
• W2978713040 hasConcept C71924100 @default.
• W2978713040 hasConcept C98274493 @default.
• W2978713040 hasConcept C99454951 @default.
• W2978713040 hasConceptScore W2978713040C112705442 @default.
• W2978713040 hasConceptScore W2978713040C121608353 @default.
• W2978713040 hasConceptScore W2978713040C126322002 @default.
• W2978713040 hasConceptScore W2978713040C142724271 @default.
• W2978713040 hasConceptScore W2978713040C143998085 @default.
• W2978713040 hasConceptScore W2978713040C197934379 @default.
• W2978713040 hasConceptScore W2978713040C204787440 @default.
• W2978713040 hasConceptScore W2978713040C27081682 @default.
• W2978713040 hasConceptScore W2978713040C2776551883 @default.
• W2978713040 hasConceptScore W2978713040C2778375690 @default.
• W2978713040 hasConceptScore W2978713040C2780192828 @default.
• W2978713040 hasConceptScore W2978713040C2908647359 @default.
• W2978713040 hasConceptScore W2978713040C61367390 @default.

• next